Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -1.02% 48.50 48.00 49.00 48.20 48.00 48.20 250,011 16:35:04
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 44.9 5.5 0.8 59.9 220

EKF Diagnostics Holdings PLC Investor results briefing update

20/03/2020 7:00am

RNS Non-Regulatory


EKF Diagnostics Holdings PLC

20 March 2020

EKF Diagnostics Holdings plc

("EKF", the "Company")

Investor results briefing update

As stated on the 4 March 2020, EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its preliminary results for the year ended 31 December 2019 on Tuesday 24 March 2020.

A briefing open to all investors was meant to take place on Tuesday 24 March 2020. The decision has been made by the management team to cancel this event. Instead the results presentation will be made available on the Company's website to download here:

If you have any questions, please contact the team at Walbrook PR on 0207 933 8780 or at

     EKF Diagnostics Holdings plc                                
     Christopher Mills, Non-Executive Chairman                                Tel: 029 2071 0570 
     Julian Baines, CEO 
     Richard Evans, FD & COO 
     N+1 Singer (Nomad & Broker)                                              Tel: 020 7496 3000 
     Aubrey Powell / George Tzimas / Carlo Spingardi (Corporate 
      Tom Salvesen (Corporate Broking) 
     Walbrook PR Limited Tel: 020 7933 8780 or 
     Paul McManus/ Lianne Cawthorne                                   Mob: 07980 541 893 / 07584 
                                                                                         391 303 

About EKF Diagnostics Holdings plc ( )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

March 20, 2020 03:00 ET (07:00 GMT)

1 Year Ekf Diagnostics Chart

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart
ADVFN Advertorial
Your Recent History
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200605 00:12:37